New drugs for treatment of hypertension.
- Author:
Chang Gyu PARK
1
Author Information
1. Department of Internal Medicine, Korea University Medical College, Seoul, Korea.
- Publication Type:Review
- MeSH:
Adrenergic Antagonists;
Aldosterone;
Amlodipine;
Angiotensin Receptor Antagonists;
Angiotensins;
Antihypertensive Agents;
Calcium;
Diuretics;
Heart Failure;
Hypertension*;
Indapamide;
Receptors, Endothelin;
Renal Insufficiency;
Renin;
Renin-Angiotensin System
- From:Korean Journal of Medicine
2004;67(5):461-466
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently several kinds of new antihypertensive agents were introduced. Diuretics such as indapamide, metyrazone and eprelerone have less side effects compared to thiazide, and have an effect in renal insufficiency. Carvedilol, combined alpha- and beta- adrenergic blocker, has a vasodilating property and an effect on heart failure. The lipid soluble third generation calcium antagonists such as amlodipine, lacidipine and lercardipine are slow onset and long acting and have less side effects, which provide continued effect even if daily doses are missed. Multiple angiotensin converting inhibitors and angiotensin receptor blockers, and the specific aldosterone antagonist eprenolone to block renin-angiotensin-aldosterone system are now available. Additionally new class antihypertensive drugs such as the vasopeptidase inhibitor, the endothelin receptor blocker and the renin inhibitor have been under investigation and shown favorable clinical results, and will be available for clinical use soon.
